Microarray and phosphokinase screenings leading to studies on ERK and JNK regulation of connective tissue growth factor expression by angiotensin II 1a and bradykinin B2 receptors in Rat1 fibroblasts.
Rat1 fibroblasts stably transfected with the rat angiotensin II (AngII) AT1a and bradykinin (BK) B2 receptor cDNAs gained the ability to bind Ang II and BK. Wild-type Rat1 cells bound neither ligand. Exposure to either effector led to characteristic Galphai and Galphaq signal cascades, the release of arachidonic acid (ARA), and the intracellular accumulation of inositol phosphates (IP). Microarray analyses in response to BK or AngII showed that both receptors markedly induce the CCN family genes, CTGF (CCN2) and Cyr61 (CCN1), as well as the vasculature-related genes, Cnn1 and Egr1. Real time PCR confirmed the increased expression of connective tissue growth factor (CTGF) mRNA. Combined sequence-based analysis of gene promoter regions with statistical prevalence analyses identified CREB, SRF, and ATF-1, downstream targets of ERK, and JNK, as prominent products of genes that are regulated by ligand binding to the BK or AngII receptors. The binding of AngII or BK markedly stimulated the phosphorylation and thus the activation of ERK2, JNK, and p38MAPK. A BKB2R and an AT1aR chimera which displayed only negligible G-protein-related signaling were constructed. Both mutant receptors continued to activate these kinases and stimulate CTGF expression. Inhibitors of ERK1/2 and JNK but not p38MAPK inhibited the BK- and AngII-stimulated expression of CTGF in cells expressing either the WT or mutant receptors, illustrating that ERK and JNK participate in the control of CTGF expression in a manner that appears to be independent of G-protein. Conversely, addition of BK or AngII to the cell line expressing WT AT1aR and BKB2R downregulated the expression of collagen alpha1(I) (COL1A1) mRNA. However, these effectors did not have this effect in cells expressing the mutant receptors. Thus, a robust G-protein related response is necessary for BK or AngII to affect COL1A1 expression.
Liu
B
B
Department of Biochemistry, Boston University School of Medicine, Boston, Massachusetts 02118, USA.
Yu
J
J
Taylor
L
L
Zhou
X
X
Polgar
P
P
D000818:Animals; D024042:Collagen Type I / Q000378:metabolism; D055513:Connective Tissue Growth Factor; D048049:Extracellular Signal-Regulated MAP Kinases / Q000502:physiology*; D005347:Fibroblasts / Q000378:metabolism; D019204:GTP-Binding Proteins / Q000502:physiology; D015971:Gene Expression Regulation, Enzymologic; D017874:Immediate-Early Proteins / Q000378:metabolism*; D036341:Intercellular Signaling Peptides and Proteins / Q000378:metabolism*; D048670:MAP Kinase Kinase 4 / Q000502:physiology*; D046228:Microarray Analysis / Q000379:methods*; D050505:Mutant Proteins / Q000378:metabolism / Q000502:physiology; D010766:Phosphorylation; D010770:Phosphotransferases / Q000032:analysis*; D012333:RNA, Messenger / Q000378:metabolism*; D051381:Rats; D044140:Receptor, Angiotensin, Type 1 / Q000502:physiology*; D043782:Receptor, Bradykinin B2 / Q000502:physiology*; D015398:Signal Transduction; D014157:Transcription Factors / Q000235:genetics; D014162:Transfection; D015854:Up-Regulation; D048051:p38 Mitogen-Activated Protein Kinases / Q000502:physiology
C526316:CCN2 protein, rat; D024042:Collagen Type I; D017874:Immediate-Early Proteins; D036341:Intercellular Signaling Peptides and Proteins; D050505:Mutant Proteins; D012333:RNA, Messenger; D044140:Receptor, Angiotensin, Type 1; D043782:Receptor, Bradykinin B2; D014157:Transcription Factors; D055513:Connective Tissue Growth Factor; D010770:Phosphotransferases; D048049:Extracellular Signal-Regulated MAP Kinases; D048051:p38 Mitogen-Activated Protein Kinases; D048670:MAP Kinase Kinase 4; D019204:GTP-Binding Proteins